AAPL333.69+3.37 (+1.02%) ▲|ABBV262.82+2.89 (+1.11%) ▲|ABT97.50+0.81 (+0.84%) ▲|ACN198.90-13.40 (-6.31%) ▼|ADBE237.69-3.59 (-1.49%) ▼|AMAT540.04+10.74 (+2.03%) ▲|AMD633.91+18.18 (+2.95%) ▲|AMGN403.04-4.23 (-1.04%) ▼|AMT162.20+1.14 (+0.71%) ▲|AMZN251.52+3.29 (+1.33%) ▲|AVGO355.14+11.50 (+3.35%) ▲|AXP302.78+0.69 (+0.23%) ▲|BA193.56+1.28 (+0.67%) ▲|BAC53.75+0.02 (+0.04%) ▲|BKNG159.02-1.26 (-0.79%) ▼|BLK1,059.63-4.73 (-0.44%) ▼|BMY61.15+0.32 (+0.53%) ▲|BNY145.40+1.48 (+1.03%) ▲|BRK-B502.65+2.15 (+0.43%) ▲|C128.50+1.50 (+1.18%) ▲|CAT845.42+19.07 (+2.31%) ▲|CL84.26-0.27 (-0.32%) ▼|CMCSA21.57-0.13 (-0.60%) ▼|COF194.72+0.24 (+0.12%) ▲|COP126.75-0.31 (-0.24%) ▼|COST920.65+5.71 (+0.62%) ▲|CRM234.69-2.00 (-0.85%) ▼|CSCO112.20+3.86 (+3.56%) ▲|CVS86.46+1.26 (+1.48%) ▲|CVX206.69-0.41 (-0.20%) ▼|DE687.00+19.74 (+2.96%) ▲|DHR214.06+2.30 (+1.09%) ▲|DIS102.19+0.86 (+0.85%) ▲|DUK114.13+0.39 (+0.34%) ▲|EMR161.61+3.04 (+1.92%) ▲|FDX290.36+3.29 (+1.15%) ▲|GD330.09-2.63 (-0.79%) ▼|GE309.56-2.83 (-0.91%) ▼|GEV988.70+1.25 (+0.13%) ▲|GILD144.74-2.76 (-1.87%) ▼|GM78.27-1.04 (-1.31%) ▼|GOOG340.35+5.42 (+1.62%) ▲|GOOGL343.50+5.26 (+1.56%) ▲|GS902.56+5.89 (+0.66%) ▲|HD282.85+0.39 (+0.14%) ▲|HON213.99+0.19 (+0.09%) ▲|IBM222.64-2.98 (-1.32%) ▼|INTC119.33-0.67 (-0.56%) ▼|INTU281.08-1.70 (-0.60%) ▼|ISRG391.95-9.29 (-2.32%) ▼|JNJ256.03-2.63 (-1.02%) ▼|JPM332.38-0.80 (-0.24%) ▼|KO85.65-0.45 (-0.52%) ▼|LIN479.48+10.03 (+2.14%) ▲|LLY1,142.85-7.00 (-0.61%) ▼|LMT505.41-0.09 (-0.02%) ▼|LOW180.80-1.58 (-0.87%) ▼|LRCX347.49+7.39 (+2.17%) ▲|MA552.26+2.26 (+0.41%) ▲|MCD231.89+0.06 (+0.03%) ▲|MDLZ58.19+0.43 (+0.74%) ▲|MDT86.38-0.06 (-0.07%) ▼|META728.08+2.15 (+0.30%) ▲|MMM161.89-1.13 (-0.69%) ▼|MO67.35+0.40 (+0.60%) ▲|MRK144.30+0.49 (+0.34%) ▲|MS190.31+2.30 (+1.22%) ▲|MSFT517.53+4.73 (+0.92%) ▲|MU1,074.89-22.50 (-2.05%) ▼|NEE76.83+0.48 (+0.63%) ▲|NFLX67.06-0.79 (-1.16%) ▼|NKE33.87-1.28 (-3.64%) ▼|NOW134.38-3.38 (-2.45%) ▼|NVDA233.95+3.09 (+1.34%) ▲|ORCL142.30+4.23 (+3.06%) ▲|PEP125.89+0.29 (+0.23%) ▲|PFE27.80-0.32 (-1.14%) ▼|PG144.91+0.96 (+0.67%) ▲|PLTR188.75-1.29 (-0.68%) ▼|PM187.46+0.88 (+0.47%) ▲|QCOM184.87+2.78 (+1.53%) ▲|RTX184.68-0.33 (-0.18%) ▼|SBUX94.71-0.17 (-0.18%) ▼|SCHW96.70-1.67 (-1.70%) ▼|SO83.72+0.25 (+0.30%) ▲|SPG200.95+0.14 (+0.07%) ▲|T24.30+0.00 (+0.00%) ▲|TMO654.80+2.29 (+0.35%) ▲|TMUS163.64+1.91 (+1.18%) ▲|TSLA370.59+16.48 (+4.65%) ▲|TXN293.80+12.49 (+4.44%) ▲|UBER68.11+0.23 (+0.34%) ▲|UNH371.90+6.70 (+1.83%) ▲|UNP278.28+5.86 (+2.15%) ▲|UPS93.02-0.87 (-0.93%) ▼|USB57.51+0.15 (+0.26%) ▲|V360.66+0.81 (+0.23%) ▲|VZ45.92-0.06 (-0.13%) ▼|WFC80.45+0.20 (+0.25%) ▲|WMT104.26+0.00 (+0.00%) ▲|XOM164.01+0.19 (+0.12%) ▲|AAPL333.69+3.37 (+1.02%) ▲|ABBV262.82+2.89 (+1.11%) ▲|ABT97.50+0.81 (+0.84%) ▲|ACN198.90-13.40 (-6.31%) ▼|ADBE237.69-3.59 (-1.49%) ▼|AMAT540.04+10.74 (+2.03%) ▲|AMD633.91+18.18 (+2.95%) ▲|AMGN403.04-4.23 (-1.04%) ▼|AMT162.20+1.14 (+0.71%) ▲|AMZN251.52+3.29 (+1.33%) ▲|AVGO355.14+11.50 (+3.35%) ▲|AXP302.78+0.69 (+0.23%) ▲|BA193.56+1.28 (+0.67%) ▲|BAC53.75+0.02 (+0.04%) ▲|BKNG159.02-1.26 (-0.79%) ▼|BLK1,059.63-4.73 (-0.44%) ▼|BMY61.15+0.32 (+0.53%) ▲|BNY145.40+1.48 (+1.03%) ▲|BRK-B502.65+2.15 (+0.43%) ▲|C128.50+1.50 (+1.18%) ▲|CAT845.42+19.07 (+2.31%) ▲|CL84.26-0.27 (-0.32%) ▼|CMCSA21.57-0.13 (-0.60%) ▼|COF194.72+0.24 (+0.12%) ▲|COP126.75-0.31 (-0.24%) ▼|COST920.65+5.71 (+0.62%) ▲|CRM234.69-2.00 (-0.85%) ▼|CSCO112.20+3.86 (+3.56%) ▲|CVS86.46+1.26 (+1.48%) ▲|CVX206.69-0.41 (-0.20%) ▼|DE687.00+19.74 (+2.96%) ▲|DHR214.06+2.30 (+1.09%) ▲|DIS102.19+0.86 (+0.85%) ▲|DUK114.13+0.39 (+0.34%) ▲|EMR161.61+3.04 (+1.92%) ▲|FDX290.36+3.29 (+1.15%) ▲|GD330.09-2.63 (-0.79%) ▼|GE309.56-2.83 (-0.91%) ▼|GEV988.70+1.25 (+0.13%) ▲|GILD144.74-2.76 (-1.87%) ▼|GM78.27-1.04 (-1.31%) ▼|GOOG340.35+5.42 (+1.62%) ▲|GOOGL343.50+5.26 (+1.56%) ▲|GS902.56+5.89 (+0.66%) ▲|HD282.85+0.39 (+0.14%) ▲|HON213.99+0.19 (+0.09%) ▲|IBM222.64-2.98 (-1.32%) ▼|INTC119.33-0.67 (-0.56%) ▼|INTU281.08-1.70 (-0.60%) ▼|ISRG391.95-9.29 (-2.32%) ▼|JNJ256.03-2.63 (-1.02%) ▼|JPM332.38-0.80 (-0.24%) ▼|KO85.65-0.45 (-0.52%) ▼|LIN479.48+10.03 (+2.14%) ▲|LLY1,142.85-7.00 (-0.61%) ▼|LMT505.41-0.09 (-0.02%) ▼|LOW180.80-1.58 (-0.87%) ▼|LRCX347.49+7.39 (+2.17%) ▲|MA552.26+2.26 (+0.41%) ▲|MCD231.89+0.06 (+0.03%) ▲|MDLZ58.19+0.43 (+0.74%) ▲|MDT86.38-0.06 (-0.07%) ▼|META728.08+2.15 (+0.30%) ▲|MMM161.89-1.13 (-0.69%) ▼|MO67.35+0.40 (+0.60%) ▲|MRK144.30+0.49 (+0.34%) ▲|MS190.31+2.30 (+1.22%) ▲|MSFT517.53+4.73 (+0.92%) ▲|MU1,074.89-22.50 (-2.05%) ▼|NEE76.83+0.48 (+0.63%) ▲|NFLX67.06-0.79 (-1.16%) ▼|NKE33.87-1.28 (-3.64%) ▼|NOW134.38-3.38 (-2.45%) ▼|NVDA233.95+3.09 (+1.34%) ▲|ORCL142.30+4.23 (+3.06%) ▲|PEP125.89+0.29 (+0.23%) ▲|PFE27.80-0.32 (-1.14%) ▼|PG144.91+0.96 (+0.67%) ▲|PLTR188.75-1.29 (-0.68%) ▼|PM187.46+0.88 (+0.47%) ▲|QCOM184.87+2.78 (+1.53%) ▲|RTX184.68-0.33 (-0.18%) ▼|SBUX94.71-0.17 (-0.18%) ▼|SCHW96.70-1.67 (-1.70%) ▼|SO83.72+0.25 (+0.30%) ▲|SPG200.95+0.14 (+0.07%) ▲|T24.30+0.00 (+0.00%) ▲|TMO654.80+2.29 (+0.35%) ▲|TMUS163.64+1.91 (+1.18%) ▲|TSLA370.59+16.48 (+4.65%) ▲|TXN293.80+12.49 (+4.44%) ▲|UBER68.11+0.23 (+0.34%) ▲|UNH371.90+6.70 (+1.83%) ▲|UNP278.28+5.86 (+2.15%) ▲|UPS93.02-0.87 (-0.93%) ▼|USB57.51+0.15 (+0.26%) ▲|V360.66+0.81 (+0.23%) ▲|VZ45.92-0.06 (-0.13%) ▼|WFC80.45+0.20 (+0.25%) ▲|WMT104.26+0.00 (+0.00%) ▲|XOM164.01+0.19 (+0.12%) ▲|
21.7 C
New York
Saturday, October 3, 2026

globenewswire

Autoimmune Collaboration and Licensing Deals Report 2025: Comprehensive Analysis of 943 Autoimmune Licensing Deals (2016-2025) Across 30+ Diseases

The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization.
The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization.

WareCRE Launches as the First Marketplace Dedicated to Co-Warehousing and Small-Bay Industrial Space for Small Businesses

WareCRE Launches as the First Marketplace Dedicated to Co-Warehousing and Small-Bay Industrial Space for Small Businesses.

Northland Power Achieves First Power on Hai Long Offshore Wind Project

Hai Long offshore substation in the Taiwan Strait.

Multiverse Computing Raises $215M to Scale Ground-Breaking Technology that Compresses LLMs by up to 95%

Technology breakthrough attracts international investment. Quantum AI leader to turbo charge AI proliferation, reduce power concerns and bring the technology to the edge
Technology breakthrough attracts international investment. Quantum AI leader to turbo charge AI proliferation, reduce power concerns and bring the technology to the edge

JCDecaux : Déclaration mensuelle d’actions et de droits de vote au 31 mai 2025

JCDecaux SE
Société Européenne à Directoire et Conseil de Surveillance
Au capital de 3.264.372,84 €
Siège Social : 17, rue Soyer - 92200 Neuilly-sur-Seine (France)
307 570 747 RCS Nanterre

Industrial Robotics Industry Forecast Report to 2035: Distribution by Type of Robot, Payload, Mobility, Application Area, End-User, Geography and Key Players

The global industrial robotics market is set to expand from USD 17.6 billion in 2025 to USD 39 billion by 2035, at a CAGR of 7.49%. Key segments include traditional and collaborative robots, with growth in payload and mobile robotics. Major players like ABB and FANUC lead in this evolving landscape.
The global industrial robotics market is set to expand from USD 17.6 billion in 2025 to USD 39 billion by 2035, at a CAGR of 7.49%. Key segments include traditional and collaborative robots, with growth in payload and mobile robotics. Major players like ABB and FANUC lead in this evolving landscape.

Iterate.ai Raises $6.4 Million from Auxier Asset Management and eBags Board Alumni to Accelerate AI Expansion

The strategic round led by Auxier Asset Management, with investments from former eBags board members Peter Cobb, Mike Edwards, and Dave Zentmyer, underscores strong confidence in Iterate’s enterprise-ready AI platform and growth vision
The strategic round led by Auxier Asset Management, with investments from former eBags board members Peter Cobb, Mike Edwards, and Dave Zentmyer, underscores strong confidence in Iterate’s enterprise-ready AI platform and growth vision

Inbjudan till webbsänd presentation och telefonkonferens i samband med SkiStar AB:s delårsrapport för tredje kvartalet 2024/25

SkiStar AB offentliggör sin delårsrapport för perioden 1 september 2024 – 31 maj 2025 torsdagen den 19 juni 2025 klockan 07.00 CEST. I samband med rapporten håller SkiStar en webbsänd presentation och telefonkonferens. Verkställande direktör Stefan Sjöstrand och ekonomi- och finansdirektör Sara J Uggelberg presenterar och kommenterar rapporten. Efter presentationen kommer det att finnas möjlighet att ställa frågor via telefon eller chatt i webbsändningen. Presentationen hålls på engelska.

Invitation to conference call with web presentation of SkiStar AB’s Interim Report for the third quarter 2024/25

SkiStar AB will publish the Interim Report for the period 1 September 2024 – 31 May 2025 on Thursday 19 June 2025 at 07.00 a.m. CEST. In connection with the report SkiStar will organize a conference call with web presentation. CEO Stefan Sjöstrand and CFO Sara J Uggelberg will present and comment on the report. After the presentation there will be time for questions, both by phone and by chat in the web presentation. The presentation will be held in English.

NewHydrogen’s Plan to Win the Green Hydrogen Race

The Company’s ThermoLoop™ technology is being developed to replace expensive electrolyzers and could upend a $12 trillion market with a flood of the world’s cheapest green hydrogen

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

SANDWICH, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present new data from its large-scale Phase II trial of LEVI-04 at EULAR, the European Congress of Rheumatology in Barcelona, Spain.

- A word from our sponsors -

spot_img

Follow us